Comparison of the Oxymask and Oxy2mask on Supplemental Oxygen Delivery

NCT ID: NCT06433934

Last Updated: 2024-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-30

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the performance of a newly released oxygen mask is the same, better, or worse than previous mask version. We will measure the flow rate necessary to maintain the same oxygen saturation in adult patients using each mask.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Southmedic, Inc. has received approval to distribute a newly designed oxygen mask. The current design has been studied and the FiO2 delivered reported to be inconsistent. The purpose of this study is to determine if the performance is the same, better, or worse than current mask. We can evaluate performance by determining Liter flow required to maintain oxygen saturations that are within limits described in NM CDH oxygen protocol. We will measure the flow rate necessary to maintain the same saturation in adult patients using both the OxyMask and Oxy2Mask. The Oxymask has a flow device inside the mask that has been revised since implementation. The mask itself is otherwise unchanged. We intend to determine if the same amount of flow results in the same outcome.

This study will include adult patients that require supplemental oxygen and we do not believe the patients will report a difference between each mask. The only variance in care is mask version used, the oxygen protocol will remain the same.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypoxia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Each patient will receive mask #1, then receive mask #2. The flowrate to maintain same desired oxygen saturations will be documented.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxy2mask

Change oxymask to oxy2mask

Group Type EXPERIMENTAL

Oxy2mask

Intervention Type DEVICE

Open design oxygen mask

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxy2mask

Open design oxygen mask

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants have oxygen device and are being titrated per NM CDH oxygen protocol (maintained between 90%-96%; or 88% - 92% if CO2 retainer)
* Participants to have period of stability; 2 hours at same liter flow on open design mask, 5-15 lpm 02.
* All adult patients (\> 18 years old) in med surge units (bed tower)
* Post-op patients requiring oxygen on Post-op Day 2.
* Patients currently on \>5 LPM via nasal cannula, clinician can recommend the change to OxyMask. If remains on \>5 LPM via OxyMask, patient can be included.
* Oxygen protocol will be followed per standards of care.

Exclusion Criteria

* Patients receiving home oxygen therapy who do not require additional oxygen during hospital stay.
* Patients with a history of Bleomycin therapy.
* Patients with a history of Paraquat poisoning
* Patients that are pregnant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Northwestern Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Patti DeJuilio

Director Respiratory Care and Diagnostic Services

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Megan Carney

Role: STUDY_DIRECTOR

Northwestern Medicine IRB

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central DuPage Hospital

Winfield, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patti DeJuilio, MS

Role: CONTACT

6309332432

Mary Henriksen, MS

Role: CONTACT

6309335875

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Oxymask

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.